Anti-GRSF1 Monoclonal Antibody for WB, IF/ICC, IP, ELISA - Q12849

Core Product Specifications and Parameters

Biological Background: GRSF1 Function and Localization

• G-rich sequence factor 1 (GRSF1) is a regulator of post-transcriptional mitochondrial gene expression, essential for mitochondrial ribosome assembly and the recruitment of mRNA and lncRNA (PubMed:23473033, PubMed:23473034). Related references: PMID:23473033, PMID:23473034
• It binds RNAs containing a 14-base G-rich element, with preference for ND6 mRNA and the long non-coding RNAs for MT-CYB and MT-ND5.
• GRSF1 facilitates the degradosome-mediated decay of non-coding mitochondrial transcripts by unwinding G-quadruplex (G4) RNA structures (PubMed:29967381). Related references: PMID:29967381
• The protein localizes to the mitochondrial matrix and can also be found in the cytoplasm.
• GRSF1 contains RNA-binding domains and is a phosphoprotein; alternative splicing produces multiple isoforms.

Experimental Guidance and Technical Tips

• The immunogen corresponds to amino acids 50–150 of human GRSF1, a region well conserved across human, mouse, and rat. The antibody is expected to recognize all major isoforms.
• For Western blot, the predicted molecular weight is ~53 kDa. Validate using mitochondrial-enriched lysates from relevant cell lines or tissues.
• In immunofluorescence/ICC, GRSF1 exhibits mitochondrial localization. Co-staining with mitochondrial markers (e.g., TOM20) is recommended to confirm specificity.
• For immunoprecipitation, the antibody can be used to enrich endogenous GRSF1 and associated RNA complexes. Include appropriate controls.
• ELISA applications may be useful for quantitative detection; optimal coating and detection conditions should be determined empirically.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio serves as a one-stop sourcing bridge for IVD raw materials, connecting diagnostic developers with high-quality antibodies and ancillary reagents. This anti-GRSF1 monoclonal antibody supports mitochondrial gene expression research and can be integrated into validated antibody pairs or custom immunoassay development. In addition to monoclonal and polyclonal antibodies against rare targets like GRSF1, we offer bulk supply of ancillary reagents and technical consulting to accelerate your project from concept to clinic.